Entera Bio

Entera Bio Financial Debt Ratio

The Financial Debt Ratio of Entera Bio (ENTX) as of Nov 22, 2026 is 3.06 %. In the previous year, Financial Debt Ratio was 2.90 % — a change of 5.77% (higher).

Financial Debt Ratio

3.06 %

YoY

5.77%

Last updated:

Financial Debt Ratio of Entera Bio is 2025 3.06 % . Financial Debt Ratio of Entera Bio was 2024 2.90 % . It decreases by 5.77% higher compared to the previous year.

The Entera Bio Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2017
29.32 USD
Jan 1, 2019
1.79 USD
Jan 1, 2020
4.44 USD
Jan 1, 2021
1.16 USD
Jan 1, 2022
0.69 USD
Jan 1, 2023
3.31 USD
Jan 1, 2024
2.90 USD
Jan 1, 2025
3.06 USD
The Entera Bio Financial Debt Ratio history
YEARFinancial Debt RatioYoY
3.06 %+5.77%
2.90 %-12.62%
3.31 %+378.19%
0.69 %-40.35%
1.16 %-73.85%
4.44 %+148.23%
1.79 %-93.89%
29.32 %-87.48%
234.17 %-20.12%
293.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Financial Debt Ratio of Entera Bio is 3.06 % in 2025.

Financial Debt Ratio of Entera Bio changed from 2.90 % to 3.06 %, representing a 5.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Entera Bio

All Key Metrics — Entera Bio